Literature DB >> 17485312

Molecular epidemiology of prostate cancer: hormone-related genetic loci.

Anand P Chokkalingam1, Frank Z Stanczyk, Juergen K V Reichardt, Ann W Hsing.   

Abstract

Prostate cancer is the most common non-skin cancer and the second leading cause of cancer deaths among men in most Western countries. Despite its high morbidity and mortality, the etiology of prostate cancer remains obscure. Although compelling laboratory data suggest a role for androgens in prostate carcinogenesis, most epidemiologic data, including serological and genetic studies, are inconclusive. In this chapter, we review the status of serologic studies and discuss the importance of intra-prostatic hormone levels in possibly clarifying the often-contradictory data on serologic studies. To provide insights and directions for epidemiologic research on hormones and prostate cancer, this review centers on the molecular epidemiology of hormone-related genetic loci. These loci have been investigated in a number of studies to date and will undoubtedly expand even further as rich new genetic information sources and high-throughput genotyping and analysis methods become available. Due to the enormous number of these loci, we recommend careful analysis and cautious interpretation of studies of genetic markers, including microsatellites and single nucleotide polymorphisms (SNPs), as false positive and negative results are likely due to limited statistical power, multiple hypothesis testing, population stratification, or non-representative population sampling. This review also highlights the need for replication in various populations, as well as reasons for performing functional analyses of SNPs, a critical and often under-appreciated component of molecular epidemiologic investigations. The time is ripe for concerted, large-scale multidisciplinary investigations that incorporate molecular genetics, biochemistry, histopathology, and endocrinology into traditional epidemiologic studies. Such collaboration will lead to a deeper understanding of the etiologic pathways of prostate cancer, ultimately yielding better preventive, diagnostic, and therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17485312     DOI: 10.2741/2325

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  11 in total

Review 1.  A perspective on the role of estrogen in hormone-induced prostate carcinogenesis.

Authors:  Maarten C Bosland
Journal:  Cancer Lett       Date:  2012-08-29       Impact factor: 8.679

2.  Evaluation of a 3-base pair indel polymorphism within pre-microRNA-3131 in patients with prostate cancer using mismatch polymerase chain reaction-restriction fragment length polymorphism.

Authors:  Mohammad Hashemi; Gholamreza Bahari; Hedieh Sattarifard; Behzad Narouie
Journal:  Mol Clin Oncol       Date:  2017-08-08

3.  The association between inflammation-related genes and serum androgen levels in men: the prostate, lung, colorectal, and ovarian study.

Authors:  Tamra E Meyer; Lisa W Chu; Qizhai Li; Kai Yu; Philip S Rosenberg; Idan Menashe; Anand P Chokkalingam; Sabah M Quraishi; Wen-Yi Huang; Jocelyn M Weiss; Rudolf Kaaks; Richard B Hayes; Stephen J Chanock; Ann W Hsing
Journal:  Prostate       Date:  2011-04-25       Impact factor: 4.104

4.  Adipokine genes and prostate cancer risk.

Authors:  Steven C Moore; Michael F Leitzmann; Demetrius Albanes; Stephanie J Weinstein; Kirk Snyder; Jarmo Virtamo; Jiyoung Ahn; Susan T Mayne; Herbert Yu; Ulrike Peters; Marc J Gunter
Journal:  Int J Cancer       Date:  2009-02-15       Impact factor: 7.396

5.  Association between single nucleotide polymorphism in miR-499, miR-196a2, miR-146a and miR-149 and prostate cancer risk in a sample of Iranian population.

Authors:  Mohammad Hashemi; Nazanin Moradi; Seyed Amir Mohsen Ziaee; Behzad Narouie; Mohammad Hosein Soltani; Maryam Rezaei; Ghazaleh Shahkar; Mohsen Taheri
Journal:  J Adv Res       Date:  2016-03-29       Impact factor: 10.479

6.  Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial.

Authors:  Jeannette M Schenk; Cathee Till; Ann W Hsing; Frank Z Stanczyk; Zhihong Gong; Marian L Neuhouser; Juergen K Reichardt; Ashraful M Hoque; William D Figg; Phyllis J Goodman; Catherine M Tangen; Ian M Thompson
Journal:  Cancer Causes Control       Date:  2015-11-20       Impact factor: 2.506

7.  Association between three genetic variants in kallikrein 3 and prostate cancer risk.

Authors:  Wei-Hong Ding; Ke-Wei Ren; Chuang Yue; Jian-Gang Zou; Li Zuo; Li-Feng Zhang; Yu Bai; Atsushi Okada; Takahiro Yasui; Yuan-Yuan Mi
Journal:  Biosci Rep       Date:  2018-11-30       Impact factor: 3.840

8.  Does exposure to agricultural chemicals increase the risk of prostate cancer among farmers?

Authors:  Marie-Elise Parent; Marie Désy; Jack Siemiatycki
Journal:  Mcgill J Med       Date:  2009-01

9.  CASP8 promoter polymorphism, mRNA expression and risk of prostate cancer among Chinese men.

Authors:  Guangbo Fu; Jialin Tang; Meilin Wang; Chao Qin; Fu Yan; Qi Ding; Changjun Yin; Xinru Wang; Zhengdong Zhang
Journal:  J Biomed Res       Date:  2011-03

10.  SHBG is an important factor in stemness induction of cells by DHT in vitro and associated with poor clinical features of prostate carcinomas.

Authors:  Yuanyuan Ma; Dongming Liang; Jian Liu; Jian-Guo Wen; Einar Servoll; Gudmund Waaler; Thorstein Sæter; Karol Axcrona; Ljiljana Vlatkovic; Ulrika Axcrona; Elisabeth Paus; Yue Yang; Zhiqian Zhang; Gunnar Kvalheim; Jahn M Nesland; Zhenhe Suo
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.